ETF Fundamental Report for IWM

Validea's fundamental report for the iShares Russell 2000 ETF (IWM), categorized as a Mid-Cap Value ETF, details its factor exposures and sector concentrations. The report highlights IWM's significant tilt towards Value (score 62) while showing very low exposure to Quality (score 7) and Low Volatility (score 14), alongside neutral Momentum (score 49). With its largest sector in Healthcare and industry in Biotechnology & Drugs, these insights are crucial for institutional investors assessing IWM's underlying risk profile and alignment with specific investment strategies.

Analysis

According to Validea's fundamental report, the iShares Russell 2000 ETF (IWM) presents a distinct factor profile primarily characterized by a significant tilt towards value, registering a score of 62 out of 99. This value orientation is sharply contrasted by its extremely low exposure to quality and low volatility, with scores of 7 and 14, respectively. This combination suggests the underlying portfolio consists of companies that are priced cheaply relative to their fundamentals but may lack strong balance sheets, stable earnings, or defensible market positions, and are prone to higher price fluctuations. The ETF's momentum exposure is neutral at 49, indicating its holdings are not defined by strong recent price trends. Furthermore, its portfolio concentration is heavily skewed towards the Healthcare sector, and more specifically, the Biotechnology & Drugs industry, adding a layer of sector-specific, often speculative, risk to its overall profile.

Key Decisions for Investors

• Investors seeking tactical exposure to the value factor within the mid-cap segment may find IWM suitable, but must be prepared to accept a significantly lower quality and higher volatility profile.
• Given the exceptionally low Quality score of 7, investors focused on capital preservation or those with a low risk tolerance should exercise caution, as the underlying holdings may possess weaker financial health and higher fundamental risk.
• Portfolio managers should be mindful of the ETF's heavy concentration in the Healthcare and Biotechnology sectors, which can introduce idiosyncratic risks and may require balancing with other, more diversified holdings to manage overall portfolio volatility.